Nucleotide sequence encoding carbamoyl phosphate synthetase II

Abstract

The present invention provides a nucleotide sequence encoding carbamoyl phosphate synthetase II of Plasmodium falciparum. Carbamoyl phosphate synthetase II catalyses the first committed and rate-limiting step in the de novo pyrimidine biosynthetic pathway. P. falciparum relies exclusively on pyrimidine synthesis de novo because of its inability to salvage pyrimidines. Mature human red blood cells, however, have no recognised requirement for a pyrimidine nucleotide. Accordingly, this enzyme represents a prime chemotherapeutic locus. The present invention relates to the use of the sequence encoding carbamoyl phosphate synthetase II in the recombinant production of carbamoyl phosphate synthetase II and to antisense molecules, ribozymes and other gene inactivation agents designed from this sequence.

Description

This is a national phase filing of PCT application PCT/AU93/00617, filed Dec. 2, 1993.

The present invention relates to nucleotide sequences encoding carbamoyl phosphate synthetase II of Plasmodium falciparum, to methods of producing this enzyme using recombinant DNA technology and to the use of this sequence and enzyme in the design of therapeutics.

BACKGROUND OF THE INVENTION

The urgency for the design of novel chemotherapeutic agents for the treatment of malaria has been renewed in recent times due to the evolution of human malarial parasites, primarily Plasmodium falciparum, which are resistant to traditional drugs. Research into a vaccine seems a very plausible alternative, but after years of investigation, no clinically acceptable product has come to date. At the same time, there is also an increasing decline in the efficacy of insecticides against mosquito vectors. At present, more than two-thirds of the world's population--approximately 500 million people--are thought to live in malaria areas (Miller, 1989). It ranks eighth in the World Health Organization's (WHO) list of ten most prevalent diseases of the world (270 million infections a year) and ranks ninth of the ten most deadly diseases, claiming over 2 million lives a year (Cox, 1991; Marshall, 1991). Though chiefly confined to poor nations, there are recent reports of infections in the United States (Marshall, 1991) and Australia (Johnson, 1991), and ever increasing cases of travellers' malaria (Steffen and Behrens, 1992).

Comparative biochemical studies between the malaria parasite, P. falciparum and its host have revealed differences in a number of metabolic pathways. One such distinction is that the parasite relies exclusively on pyrimidine synthesis de novo because of its inability to salvage preformed pyrimidines (Sherman, 1979). Moreover, the mature human red blood cell has no recognised requirement for pyrimidine nucleotides (Gero and O'Sullivan, 1990). Major efforts have been directed towards the development of inhibitors of the pyrimidine biosynthetic pathway (Hammond et al., 1985; Scott et al., 1986; Prapunwattana et al., 1988; Queen et al., 1990; Krungkrai et al., 1992), confirming its potential as a chemotherapeutic locus. Current research into the molecular biology of the key pyrimidine enzymes is envisioned as a powerful tool, not only to get a better understanding of the parasite's biochemistry, but also to explore specific differences between the parasite and the mammalian enzymes.

Glutamine-dependent carbamoyl phosphate synthetase (CPSII, EC 6.3.5.5) catalyses the first committed and rate-limiting step in the de novo pyrimidine biosynthetic pathway of eukaryotic organisms (Jones, 1980). Moreover, because it catalyzes a complex reaction involving three catalytic units and several substrates and intermediates, it is a very interesting enzyme to study from a biochemical point of view. The structural relationship of CPSII to other pyrimidine enzymes varies in different organisms, making it a good subject for evolutionary studies.

The paucity of material that can be obtained from malarial cultures has hampered the isolation of adequate amounts of pure protein for analysis. The difficulty in purifying CPS is further augmented by its inherent instability. Studies using crude extracts from P. berghei (a rodent malaria) revealed a high molecular weight protein containing CPS activity, which was assumed to be associated with ATCase (Hill et al., 1981), a situation also found in yeast (Makoff and Radford, 1978). However, recent analysis by Krungkrai and co-workers (1990) detected separate CPSII and ATCase activities in P. berghei. Although CPS activity has been detected in P. falciparum (Reyes et al., 1982) until this current study there is no indication of its size nor its linkage with other enzymes in the pathway.

The glutamine-dependent activity of CPSII can be divided into two steps: (1) a glutaminase (GLNase) reaction which hydrolyzes glutamine (Gln) and transfers ammonia to the site of the carbamoyl phosphate synthetase; and (2) a synthetase reaction where carbamoyl phosphate is synthesised from two molecules of adenosine triphosphate (ATP), bicarbonate and ammonia. The second activity involves three partial reactions: (a) the activation of bicarbonate by ATP; (b) the reaction of the activated species carboxyphosphate with ammonia to form carbamate; and (c) the ATP-dependent phosphorylation of carbamate to form carbamoyl phosphate (powers and Meister, 1978). Hence, there are two major domains in CPSII, the glutamine amidotransferase domain (GAT) and the carbamoyl phosphate synthetase domain (CPS) or simply synthetase domain. The glutaminase domain (GLNase) is a subdomain of GAT, while there are two ATP-binding subdomains in the synthetase domain.

In view of the similarities between the glutamine amidotransferase domain of CPS and other amidotransferases, it has been proposed that these subunits arose by divergent evolution from a common ancestral gene (=20 kDa) representing the GLNase domain and that particular evolution of the CPS GAT domain (=42 kDa which includes the putative structural domain only present in CPS) must have involved fusions and/or insertions of other sequences (Werner et al., 1985). The GAT of mammalian CPSI gene has been proposed to be formed by a simple gene fusion event at the 5' end of this ancestral gene with an unknown gene (Nyunoya et al., 1985).

The genes for the larger synthetase domains of various organisms were postulated to have undergone a gene duplication of an ancestral kinase gene resulting in a polypeptide with two homologous halves (Simmer et al., 1990). Unlike the subunit structure of E. coli and arginine-specific CPS of yeast, a further fusion of the genes encoding GAT and the synthetase domains was suggested to have formed the single gene specific for pyrimidine biosynthesis in higher eukaryotes. Conversely, Simmer and colleagues (1990) proposed that the arginine-specific CPS's (like cpa1 and cpa2 in yeast) as well as rate mitochondrial CPSI arose by defusion from the pyrimidine chimera.

DESCRIPTION OF THE INVENTION

The present inventors have isolated and characterised the complete gene encoding the CPSII enzyme from P. falciparum (pfCPSII). Reported here is the sequence including 5' and 3' untranslated regions. In so doing, the present inventors have identified the respective glutaminase and synthetase domains. Unlike CPSII genes in yeast, D. discoideum, and mammals, there is no evidence for linkage to the subsequent enzyme, aspartate transcarbamoylase (ATCase). This is in contrast to the report by Hill et al., (1981) for the enzymes from P. berghei. The present inventors have, however, found two large inserts in the P. falciparum gene of a nature that does not appear to have been previously described.

Accordingly, in a first aspect, the present invention consists in a nucleic acid molecule encoding carbamoyl phosphate synthetase II of Plasmodium falciparum, the nucleic acid molecule including a sequence substantially as shown in Table 1 from 1 to 7176, or from 1 to 750, or from 751 to 1446, or from 1447 to 2070, or from 2071 to 3762, or from 3763 to 5571, or from 5572 to 7173, or from 1 to 3360, or from 2071 to 6666, or from 2071 to 7173, or a functionally equivalent sequence.

In a preferred embodiment of the present invention, the nucleic acid molecule includes a sequence shown in Table 1 from -1225 to 7695 or a functionally equivalent sequence.

In a second aspect, the present invention consists in an isolated polypeptide, the polypeptide including an amino acid sequence substantially as shown in Table 1 from 1 to 2391, from 483 to 690, from 691 to 1254, 1858 to 2391, from 1 to 1120, from 691 to 2222, or from 691 to 2391.

As used herein the term "functionally equivalent sequence" is intended to cover minor variations in the nucleic acid sequence which, due to degeneracy in the code, do not result in the sequence encoding a different polypeptide.

In a third aspect the present invention consists in a method of producing Plasmodium falciparum carbamoyl phosphate synthetase II, the method comprising culturing a cell transformed with the nucleic acid molecule of the first aspect of the present invention under conditions which allow expression of the nucleic acid sequence, and recovering the expressed carbamoyl phosphate synthetase II.

The cells may be either bacteria or eukaryotic cells. Examples of preferred cells include E. coli, yeast, and Dictyostelium discoideum.

As will be readily understood by persons skilled in this field, the elucidation of the nucleotide sequence for CPSII enables the production of a range of therapeutic agents. These include antisense nucleotides, ribozymes, and the targeting of RNA and DNA sequences using other approaches, e.g., triplex formation.

As can be seen from a consideration of the sequence set out in Table 1 the Plasmodium falciparum CPSII gene includes two inserted sequences not found in other carbamoyl phosphate synthetase genes. The first inserted sequence separates the putative structural domain and the glutiminase domain whilst the second inserted sequence separates the two ATP binding subdomains of the synthetase subunit CPSa and CPSb.

TABLE 1__________________________________________________________________________Nucleotide and Deduced Amino Acid Sequence of theCarbamoyl Phosphate Synthetase II Gene from Plasmodiumfalciparum (SEQ ID NOS: 1 and 2)__________________________________________________________________________ ##STR1## ##STR2## ##STR3## ##STR4## ##STR5## ##STR6## ##STR7## ##STR8## ##STR9## ##STR10## ##STR11## ##STR12## ##STR13## ##STR14## ##STR15## ##STR16## ##STR17## ##STR18## ##STR19## ##STR20## ##STR21## ##STR22## ##STR23## ##STR24## ##STR25## ##STR26## ##STR27## ##STR28## ##STR29## ##STR30## ##STR31## ##STR32## ##STR33## ##STR34## ##STR35## ##STR36## ##STR37## ##STR38## ##STR39## ##STR40## ##STR41## ##STR42## ##STR43## ##STR44## ##STR45## ##STR46## ##STR47## ##STR48## ##STR49## ##STR50## ##STR51## ##STR52## ##STR53## ##STR54## ##STR55## ##STR56## ##STR57## ##STR58## ##STR59## ##STR60## ##STR61## ##STR62## ##STR63## ##STR64## ##STR65## ##STR66## ##STR67## ##STR68## ##STR69## ##STR70## ##STR71## ##STR72## ##STR73## ##STR74## ##STR75## ##STR76## ##STR77## ##STR78## ##STR79## ##STR80## ##STR81## ##STR82## ##STR83## ##STR84## ##STR85## ##STR86## ##STR87## ##STR88## ##STR89## ##STR90## ##STR91## ##STR92## ##STR93## ##STR94## ##STR95## ##STR96## ##STR97## ##STR98## ##STR99## ##STR100## ##STR101## ##STR102## ##STR103## ##STR104## ##STR105## ##STR106## ##STR107## ##STR108## ##STR109## ##STR110## ##STR111## ##STR112## ##STR113## ##STR114## ##STR115## ##STR116## ##STR117## ##STR118## ##STR119## ##STR120## ##STR121## ##STR122## ##STR123## ##STR124## ##STR125## ##STR126## ##STR127## ##STR128## ##STR129## ##STR130## ##STR131## ##STR132## ##STR133## ##STR134## ##STR135## ##STR136## ##STR137## ##STR138## ##STR139## ##STR140## ##STR141## ##STR142## ##STR143## ##STR144## ##STR145## ##STR146## ##STR147## ##STR148## ##STR149## ##STR150##__________________________________________________________________________ The GAT domain is make up of two subdomains: a putative structural domain (1750) and a glutaminase domain (1447-2070). These two subdomains are separated by a first inserted sequence (751-1446, underlined). The two AT binding subdomains of the synthetase subunit, CPSa (2071-3762) and CPSb (5572-5173) are separated by a second inserted sequence (3763-5571, underlined).

As these inserted sequences are not found in other carbamoyl phosphate synthetase genes they represent prime targets for therapies including, but not limited to, antisense nucleotides, ribozymes and triplex forming nucleotides as there is a decreased likelihood of deleterious reaction with host homologues of the gene.

Antisense RNA molecules are known to be useful for regulating gene expression within the cell. Antisense RNA molecules which are complementary to portion(s) of CPSII can be produced from the CPSII sequence. These antisense molecules can be used as either diagnostic probes to determine whether or not the CPSII gene is present in a cell or can be used as a therapeutic to regulate expression of the CPSII gene. Antisense nucleotides prepared using the CPSII sequence include nucleotides having complementarity to the CPSII mRNA and capable of interfering with its function in vivo and genes containing CPSII sequence elements that can be just transcribed in living cells to produce antisense nucleotides. The genes may include promoter elements from messenger RNA (polymerase II) from cells, viruses, pathogens or structural RNA genes (polymerase I & III) or synthetic promoter elements. A review of antisense design is provided in "Gene Regulation: Biology of Antisense RNA and DNA" R. P. Eirckson and J. G. Izant, Raven Press 1992. Reference may also be had to U.S. Pat. No. 5,208,149 which includes further examples on the design of antisense nucleotides. The disclosure of each of these references is incorporated herein by reference.

As used herein the term "nucleotides" include but are not limited to oligomers of all naturally-occurring deozyribonucleotides and ribonucleotides as well as any nucleotide analogues. Nucleotide analogues encompass all compounds capable of forming sequence-specific complexes (eg duplexes or hetroduplexes) with another nucleotide including methylphosphonates or phosphorothioates but may have advantageous diffusion or stability properties. The definition of nucleotides includes natural or analogue bases linked by phosphodiester bonds, peptide bonds or any other covalent linkage. These nucleotides may be synthesised by any combination of in vivo in living cells, enzymatically in vitro or chemically.

Ribozymes useful in regulating expression of the CPSII gene include nucleotides having CPSII sequence for specificity and catalytic domains to promote the cleavage of CPSII mRNA in vitro or in vivo. The catalytic domains include hammerheads, hairpins, delta-virus elements, ribosome RNA introns and their derivatives. Further information regarding the design of ribozymes can be found in Haseloff, J. & Gerlach, W. L. (1988) Nature 334, 585; Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E. & Cech, T. R. (1982) Cell 31, 147; International Patent Application No. WO 88/04300, U.S. Pat. Nos. 4,987,071 and 5,254,678. The disclosure of each of these references is incorporated herein by reference. The catalytic elements may enhance the artificial regulation of a CPSII target mRNA by accelerating degradation or some other mechanism.

Triple helix oligonucleotides can be used to inhibit transcription from the genome. Given the sequence provided herein for the CPSII gene it will now be possible to design oligonucleotides which will form triplexes thereby inhibiting transcription of the CPSII gene. Information regarding the generation of oligonucleotides suitable for triplex formation can be found in a Griffin et al (Science 245: 967-971(1989)) this disclosure of this reference is incorporated herein by reference.

Triplex agents include all nucleotides capable of binding to the CPSII gene through formation of the complex with DNA or chromatin. The interaction can be through formation of a triple-stranded Hoogsteen structure or other mechanisms such as strand invasion that relies on the CPSII sequence information.

Accordingly, in a fourth aspect the present invention consists in a ribozyme capable of cleaving carbamoyl phosphate synthetase II mRNA, the ribozyme including sequences complementary to portions of mRNA obtained from the nucleic acid molecule of the first aspect of the present invention.

In a preferred embodiment of this aspect of the present invention the ribozyme includes sequences complementary to mRNA obtained from the first or second inserted sequences of the nucleic acid molecule of the first aspect of the present invention.

In a fifth aspect the present invention consists in an antisense oligonucleotide capable of blocking expression of the nucleic acid molecule of the first aspect of the present invention.

As stated above, in one aspect the present invention relates to a method of producing CPSII by rcombinant technology. The protein produced by this method and the polypeptides of the present invention will be useful in in vitro drug binding studies in efforts to develop other anti-malarial therapeutics.

In order that the nature of the present invention may be more clearly understood the method by which the P. falciparum CPSII gene was cloned will now be described with reference to the following example and Figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a summary of a "gene walking" strategy used to clone and sequence the full length P. falciparum carbamoyl phosphate synthetase II gene.

EXAMPLE

The conventional way to screen for genes of which the amino acid sequence had not been previously determined is via heterologous probing, i.e. with gene fragments of the target enzyme from closely related organisms. This has proved to be unsuccessful for several workers with Plasmodium falciparum largely due to the unusually high A-T content of its genome. After initial unfruitful attempts to isolate the CPSII gene in Plasmodium falciparum using a yeast ura2 gene fragment (Souciet et al., 1989), the present invention opted to amplify part of the CPSII gene using the polymerase chain reaction (PCR) (Saiki et al.,1988) with a view to use the amplified product as probe for screening.

The present invention isolated and cloned a PCR product using oligonucleotides designed from conserved sequences from the amino terminal GAT domain and the first half of the synthetase domain of the CPS gene. Nucleotide sequencing confirmed that a portion of the CPSII gene had been obtained. Total parasite DNA was fragmented with a restriction enzyme and subjected to Southern analysis using the CPSII-specific gene probe. The sizes of DNA fragments hybridizing to the gene probe were determined then the DNA in the corresponding bands were used for the construction of a "mini-library". In this way a smaller population of clones were screened for the pf CPSII gene.

To isolate the full length of pf CPSII gene, a series of mini-libraries were constructed utilising different segments of known sequence to gain information of the unknown flanking regions both towards the 5' and 3' termini of the gene using "gene-walking". The strategy employed is summarized in FIG. 1.

In the first Southern analysis, total P. falciparum DNA was digested with HindIII and EcoRI and hybridisation was carried out using the pfCPSII 453 PCR product. A 3.0 kb HindIII and a smaller EcoRI fragment hybridised to the probe. Subsequent screening of a HindIII pTZ18U mini-library resulted in the isolation of a recombinant that contained a 3.0 kb pfCPSII gene fragment, CPS2. The 453 bp PCR product was localised in the middle of this segment.

Two regions from both the 5' and 3' ends of CPS2 were used to isolate neighbouring sequences at either end in order to obtain the further gene sequences. A HindIII/EcoRI fragment from the 5' end of CPS2 was instrumental in isolating a further 1.5 kb fragment, CPS1 consisting of the complete 5' region of the gene and some non-encoding sequences.

A 550 bp inverse PCR (IPCR; Triglia et al., 1988) product was obtained with the aid of known sequences from the 3' end of CPS2.

This IPCR product was used to screen for the 3' region flanking CPS2. A 3.3 kb HindIII recombinant containing CPS3 as well as a related 3.3 kb XBaI clone (not presented in FIG. 1) were isolated by the mini-library technique. Using a 200 bp XbaI/HindIII fragment from the 3' end of CPS3, a 1.3 kb XbaI segment, CPS4 was cloned which contained the putative stop codon and some 3' non-coding region.

Combining these four gene gragments (CPS1, CPS2, CPS3 and CPS4) excluding their overlaps, gives a total of 8.8 kb consisting of approximately 7.0 kb coding and 1.8 flanking sequences.

The complete nucleotide sequence of the CPSII gene in P. falciparum, together with its 5' and 3' flanking sequences, is presented in Table 1.

As will be readily appreciated by those skilled in the art the isolation of this gene and its sequencing by the present inventors opens up a range of new avenues for treatment of Plasmodium falciparum infection. The present invention enables the product of quantities of the Plasmodium falciparum carbamoyl phosphate synthetase II enzyme using recombinant DNA technology. Characterisation of this enzyme may enable its use as a chemotherapeutic loci.

The isolation of this gene also will enable the production of antisense molecules, ribozymes or other gene inactivation agents which can be used to prevent the multiplication of the parasite in infected individuals.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

REFERENCES

Cox, F. E. G. (1991) Malaria vaccines: while we are waiting. Parasitology Today 7: 189-190

Gero, A. M. and O'Sullivan, W. J. (1991) Purines and pyrimidines in malarial parasites. Blood Cells 16: 467-498

Hammond, D. J. Burchell, J. R. and Pudrey, M. (1985) Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2.(4.t-butylcyclohexyl)-3-hydroxy-1, 4-naphthoquinine in vitro. Mol. Biochem. Parasitol 14: 97-109

Hill, B., Kilsby, J. Rogerson, G. W., McIntosh, R. T. and Ginger, C. D. (1981). The Enzymes of pyrimidine biosynthesis in a range of parasitic protozoa and helminths. Mol. Biochem. Parasitol. 2: 123-134.

Johnson, C. Malaria back to plague us. Sydney Morning Herald, Nov. 13, 1991.

Jones, M. E. (1980) Pyrimidine nucleotide biosynthesis in animals: genes, enzymes and regulation of UMP biosynthesis. Annu. Rev. Biochem. 49: 253-279.

Krungkrai, J. Cerami, A. and Henderson, G. B. (1990) Pyrimidine biosynthesis in parasitic protozoa: purification of a monofunctional dihydroorotase from Plasmodium berghei and Crithidia fasciculata. Biochemistry 29: 6270-6275.

Krungkrai, J. Krungkrai, S. R. and Phakanont, K. (1992) Antimalarial activity of orotate analogs that inhibit dihydrootase and dihydroorotate dehydrogenase. Biochem. Pharmacol. 43: 1295-1301.

Marshal, E. (1991) Malaria parasite gaining ground against science. Science 2: 190.

Nyunoya, H., Broglie, K. E., Widgren, W. E. and Lusty C. J. (1985) Characterization and derivation of the gene coding for mitochondrial carbamyl phosphate synthetase I of rat. J. Biol. Chem. 260: 9346-9356.

Prapunwattana, P., O'Sullivan, W. J. and Yuthavong, Y. (1988) Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in in vitro culture by tetracycline. Mol. Biochem. 27: 119-124.

Queen, S. A., Vander Jagt, D. L. and Reyes, P. (1990) In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism. Antimicrob. Agents Chemother. 34: 1393-1398.

Reyes, P., Rathod, P. K., Sanchez, D. J. Mrema, J. E. K., Rieckmann, K. H. and Heidrich, H. G. (1982) Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 5: 275-290.

Rubino S. D., Nyunoya, H. and Lusty, C. J. (1986) JBC 261(24):11320-11327.

Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis K. B. and Erlich H. A. (1988) Science 239:487-491.

Scott, H. V., Gero, A. M. and O'Sullivan, W. J. (1986) In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol. Biochem. Parasitol. 18: 3-15.

Sherman, I. W. (1979) Biochemistry of Plasmodium (malarial parasites) Microbiol. Rev. 43: 453-495.

Simmer, J. P., Kelly, R. E., Rinker, Jr., A. G., Scully, J. L. and Evans D. R. (1990) Mammalian carbamyl phosphate synthetase (CPS). J. Biol. Chem 265: 10395-10402.

Simmer, J. P., Kelly, R. E., Austin, G. R., Jr., Scully, J. L. and Evans, D. R. (1990) JBC 285(18):10395-10402.

Souciet, J. L., Nagy, M., Le Gouar, M., Lacroute, F. and Potier, S. (1989) Gene (Amst.) 79: 59-70.

Triglia, T., Peterson, M. G. and Kemp, D. J. (1988) PNAS 16:8186.

Werner, M., Feller, A. and Pierard, A. (1985) Nucleotide sequence of yeast gene CPA1 encoding the small subunit of argine-pathway carbamoyl-phosphate synthetase. Eur. J. Biochem. 146: 371-381.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 2(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 8920 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: genomic(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:GAATTCCTTCAGCCAAAAAAAATGACAACGCAAATTTTAAGAAAAGAAAAACAATCGACT60CGTCTTTGAATGAGGTTAGAAATTCGATACGTGAAAGGGACTTAAGAAGGCTTAACAGAG120AAAAGAGTAAAATCTTATAAGCATTTGAAGGAAAAAATAATAAAATAAAAAAATAAAAAG180ATAAAAAATATTTATATTTGATATGTAGTATATATAATGATTATTCATATTAATAACATA240GATAAAAAACTTTTTTTTTTTTTTTTTTTCTTTATATTTATTAACAATACATTTAAGTTA300TTTTATATATATATATATATATATATATATATATATATATATATATGTTTGTGTGTTCAT360TTGTTTATAAAATTACTTGAAATATAAAACTTATTAATATATTTCCAATTAATATGAATA420CAATTATTAATATTTTGATGTGTACACATTAATATAGTTTTACACTTCTTATAATAAAAC480CATCCTATATATTATACACAATATATAATACTCCCCAATATTGTGGTTCCTATAATTTTA540TTTATATATTTATTTATTAATTTATTCATTTATTTATTTTTTTTCTTAGTTTATAAAATA600GTAATTCTACTAATTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAATT660TACATATGAAAAATGAACTTGTATATGTAAATTTATAAATATTTTAAACATAAATATAAA720TGTATAAAAAAAAAAAAGAAAAATGGGAAAAAATAATATAGATATATATATAAATATATA780TATATATATAATTATTGGGGATATTCTCTGAATCATAGGTCTTAAACAGTTTTATTCTTT840TAACATCACAAAGTTGTTATTAAAAGTATATATATCTTATTGGTTCCTATATAAAACTAT900AGTATTCTATAATATATTCTGTATATTTCATTTTATCATTTGTAAGCAATCCCTATTTAT960TATAATTATTATTTTTTTTTTTATAAAAGAGGTATAAAACAGTTTATTCAATTTTTTTCC1020TAAAGGAGCAACCTTCAGTCAATTTACATTTTCCACCGGTTGGTTGGCACAACATAATGT1080TACAGCTAAAAAAAGAAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATATATATAT1140ATATATATATATATACATAATATGTACAATGCTACCATACAAGTATATAAATTTTTCAAC1200ATTGTTGTGATGTTGCATTTTTCTTATGTATATTTCTTTTAAATATAATTTATATATATA1260TATATATATATATATATATATATTTGTTCTTATAGATTTTAAAACAGTTGGGAGGTTAAT1320TCTTGAAGATGGTAACGAATTTGTAGGGTACAGTGTAGGTTACGAAGGGTGTAAAGGAAA1380TAATAGTATATCATGTCATAAGGAGTATAGAAATATTATTAATAATGATAATAGCAAGAA1440TAGTAATAATTCATTTTGTAATAATGAAGAAAACAATTTGAAAGATGATTTATTATATAA1500AAATAGTCGATTAGAAAATGAAGATTTTATTGTTACAGGTGAAGTTATATTTAATACAGC1560TATGGTTGGATATCCTGAAGCTTTAACGGACCCAAGTTATTTTGGTCAAATATTAGTTTT1620AACATTTCCTTCTATTGGTAATTATGGTATTGAAAAAGTAAAACATGATGAAACGTTTGG1680ATTAGTACAAAATTTTGAAAGTAATAAAATTCAAGTACAAGGTTTAGTTATTTGTGAATA1740TTCGAAGCAATCATATCATTACAATTCTTATATTACCTTAAGTGAATGGTTAAAGATTTA1800TAAAATTCCATGTATAGGTGGTATAGATACAAGAGCCTTAACAAAACTTTTAAGAGAAAA1860AGGTAGTATGTTAGGTAAAATAGTTATATATAAAAACAGACAACATATTAATAAATTATA1920TAAAGAAATTAATCTTTTTGATCCTGGTAATATAGATACTCTAAAATATGTATGTAATCA1980TTTTATACGTGTTATTAAGTTGAATAATATTACATATAATTATAAAAATAAGGAAGAATT2040TAATTATACCAATGAAATGATTACTAATGATTCTTCAATGGAAGATCATGATAATGAAAT2100TAATGGTAGTATTTCTAATTTTAATAATTGTCCAAGTATCTCTAGTTTTGATAAAAGTGA2160ATCGAAAAATGTTATTAATCATACATTGTTAAGAGATAAAATGAACCTAATAACTTCATC2220TGAAGAATATCTGAAAGATCTTCATAATTGTAATTTTAGTAATAGTAGTGATAAAAATGA2280TTCTTTTTTTAAGTTATATGGTATATGTGAATATGATAAATATTTAATTGACCTTGAAGA2340AAATGCTAGCTTTCATTATAATAATGTAGATGAATATGGATATTATGATGTTAATAAAAA2400TACAAATATTCTATCTAATAATAAAATAGAACAAAACAACAATAACGAAAATAACAAAAA2460TAACAAAAATAACAACAATAACGAGGTTGATTATATAAAGAAAGATGAGGATAATAATGT2520CAATAGTAAGGTCTTTTATAGCCAATATAATAATAATGCACAAAATAATGAACATACCGA2580ATTTAATTTAAATAATGATTATTCTACTTATATTAGAAAGAAAATGAAAAATGAAGAATT2640CCTTAATTTGGTAAACAAAAGAAAAGTAGACCATAAAGAAAAAATTATTGTTATTGTTGA2700TTGTGGTATTAAAAATAGTATAATCAAAAATTTAATAAGACACGGTATGGATCTTCCATT2760AACATATATTATTGTACCTTATTATTACAATTTTAATCATATAGATTATGATGCAGTTCT2820TTTATCTAATGGTCCTGGAGATCCTAAAAAGTGTGATTTCCTTATAAAAAATTTGAAAGA2880TAGTTTAACAAAAAATAAAATTATATTTGGTATTTGTTTAGGTAATCAACTATTAGGTAT2940ATCATTAGGTTGTGACACATATAAAATGAAATATGGTAATAGAGGTGTTAATCAACCCGT3000AATACAATTAGTAGATAATATATGTTACATTACCTCACAAAATCATGGATACTGTTTAAA3060GAAAAAATCAATTTTAAAAAGAAAAGAGCTTGCGATTAGTTATATAAATGCTAATGATAA3120ATCTATAGAAGGTATTTCACATAAAAATGGAAGATTTTATAGTGTCCAGTTTCATCCTGA3180GGGTAATAATGGTCCTGAAGATACATCATTTTTATTTAAGAATTTTCTTTTAGATATCTT3240TAATAAGAAAAAACAATATAGAGAATATTTAGGATATAATATTATTTATATAAAAAAGAA3300AGTGCTTCTTTTAGGTAGTGGTGGTTTATGTATAGGACAAGCAGGAGAATTCGATTATTC3360AGGAACACAAGCAATTAAAAGTTTAAAAGAATGTGGTATATATGTTATATTAGTTAATCC3420TAACATAGCAACTGTTCAAACATCAAAAGGTTTGGCAGATAAGGTATACTTTTTACCAGT3480TAATTGTGAATTTGTAGAAAAAATTATTAAAAAGGAAAAACCTGATTTTATTTTATGTAC3540ATTTGGTGGTCAGACAGCTTTAAATTGTGCTTTAATGTTAGATCAAAAAAAAGTATTGAA3600AAAGAATAATTGTCAATGTTTAGGTACATCTTTAGAATCTATAAGAATAACAGAAAATAG3660AACATTATTTGCTGAAAAATTAAAAGAAATTAATGAAAGAATAGCTCCATATGGTAGTGC3720AAAAAATGTTAATCAAGCTATTGATATAGCTAATAAAATAGGATATCCAATATTAGTACG3780TACAACATTTTCGTTAGGAGGATTAAATAGTAGTTTCATAAATAATGAAGAAGAACTTAT3840CGAAAAATGTAATAAAATATTTTTACAAACTGATAATGAAATATTTATAGATAAATCATT3900ACAAGGATGGAAAGAAATAGAATATGAATTATTAAGAGATAATAAAAATAATTGTATAGC3960TATATGTAATATGGAAAATATAGATCCATTAGGTATACATACAGGAGATAGTATAGTTGT4020TGCACCTTCACAAACATTAAGTAATTATGAATATTATAAATTTAGAGAAATAGCATTAAA4080GGTAATTACACATTTAAATATTATAGGAGAATGTAATATACAATTTGGTATAAATCCACA4140AACAGGAGAATATTGTATTATTGAAGTTAATGCTAGGCTTAGTAGAAGTTCAGCATTAGC4200TTCTAAAGCTACTGGTTATCCACTTGCTTATATATCAGCAAAAATAGCCTTGGGATATGA4260TTTGATAAGTTTAAAAAATAGCATAACTAAAAAAACAACTGCCTGTTTTGAACCCTCTCT4320AGATTACATTACAACAAAAATACCACGATGGGATTTAAATAAATTTGAGTTTGCTTCTAA4380TACAATGAATAGTAGTATGAAAAGTGTAGGAGAAGTTATGTCTATAGGTAGAACCTTTGA4440AGAATCTATACAAAAATCTTTAAGATGTATTGATGATAATTATTTAGGATTTAGTAATAC4500GTATTGTATAGATTGGGATGAAAAGAAAATTATTGAAGAATTAAAAAATCCATCACCAAA4560AAGAATTGATGCTATACATCAAGCTTTCCATTTAAATATGCCTATGGATAAAATACATGA4620GCTGACACATATTGATTATTGGTTCTTACATAAATTTTATAATATATATAATTTACAAAA4680TAAGTTGAAAACGTTAAAATTAGAGCAATTATCTTTTAATGATTTGAAGTATTTTAAGAA4740GCATGGTTTTAGTGATAAGCAAATAGCTCACTACTTATCCTTCAACACAAGCGATAATAA4800TAATAATAATAATAATATTAGCTCATGTAGGGTTACAGAAAATGATGTTATGAAATATAG4860AGAAAAGCTAGGATTATTTCCACATATTAAAGTTATTGATACCTTATCAGCCGAATTTCC4920GGCTTTAACTAATTATTTATATTTAACTTATCAAGGTCAAGAACATGATGTTCTCCCATT4980AAATATGAAAAGGAAAAAGATATGCACGCTTAATAATAAACGAAATGCAAATAAGAAAAA5040AGTCCATGTCAAGAACCACTTATATAATGAAGTAGTTGATGATAAGGATACACAATTACA5100CAAAGAAAATAATAATAATAATAATATGAATTCTGGAAATGTAGAAAATAAATGTAAATT5160GAATAAAGAATCCTATGGCTATAATAATTCTTCTAATTGTATCAATACAAATAATATTAA5220TATAGAAAATAATATTTGTCATGATATATCTATAAACAAAAATATAAAAGTTACAATAAA5280CAATTCCAATAATTCTATATCGAATAATGAAAATGTTGAAACAAACTTAAATTGTGTATC5340TGAAAGGGCCGGTAGCCATCATATATATGGTAAAGAAGAAAAGAGTATAGGATCTGATGA5400TACAAATATTTTAAGTGCACAAAATTCAAATAATAACTTTTCATGTAATAATGAGAATAT5460GAATAAAGCAAACGTTGATGTTAATGTACTAGAAAATGATACGAAAAAACGAGAAGATAT5520AAATACTACAACAGTATTTATGGAAGGTCAAAATAGTGTTATTAATAATAAGAATAAAGA5580GAATAGTTCTTTATTGAAAGGTGATGAAGAAGATATTGTGATGGTAAATTTAAAAAAGGA5640AAATAATTATAATAGTGTAATTAATAATGTAGATTGTAGGAAAAAGGATATGGATGGAAA5700AAATATAAATGATGAATGTAAAACATATAAGAAAAATAAATATAAAGATATGGGATTAAA5760TAATAATATAGTAGATGAGTTATCCAATGGAACATCACATTCAACTAATGATCATTTATA5820TTTAGATAATTTTAATACATCAGATGAAGAAATAGGGAATAATAAAAATATGGATATGTA5880TTTATCTAAGGAAAAAAGTATATCTAATAAAAACCCTGGTAATTCTTATTATGTTGTAGA5940TTCCGTATATAATAATGAATACAAAATTAATAAGATGAAAGAGTTAATAGATAACGAAAA6000TTTAAATGATGAATATAATAATAATGTTAATATGAATTGTTCTAATTATAATAATGCTAG6060TGCATTTGTAAATGGAAAGGATAGAAATGATAATTTAGAAAATGATTGTATTGAAAAAAA6120TATGGATCATACATACAAACATTATAATCGTTTAAACAATCGTAGAAGTACAAATGAGAG6180GATGATGCTTATGGTAAACAATGAAAAAGAGAGCAATCATGAGAAGGGCCATAGAAGAAA6240TGGTTTAAATAAAAAAAATAAAGAAAAAAATATGGAAAAAAATAAGGGAAAAAATAAAGA6300CAAAAAGAATTATCATTATGTTAATCATAAAAGGAATAATGAATATAATAGTAACAATAT6360TGAATCGAAGTTTAATAATTATGTTGATGATATAAATAAAAAAGAATATTATGAAGATGA6420AAATGATATATATTATTTTACACATTCGTCACAAGGTAACAATGACGATTTAAGTAATGA6480TAATTATTTAAGTAGTGAAGAATTGAATACTGATGAGTATGATGATGATTATTATTATGA6540TGAAGATGAAGAAGATGACTATGACGATGATAATGATGATGATGATGATGATGATGATGA6600TGGGGAGGATGAGGAGGATAATGATTATTATAATGATGATGGTTATGATAGCTATAATTC6660TTTATCATCTTCAAGAATATCAGATGTATCATCTGTTATATATTCAGGGAACGAAAATAT6720ATTTAATGAAAAATATAATGATATAGGTTTTAAAATAATCGATAATAGGAATGAAAAAGA6780GAAAGAGAAAAAGAAATGTTTTATTGTATTAGGTTGTGGTTGTTATCGTATTGGTAGTTC6840TGTAGAATTTGATTGGAGTGCTATACATTGTGTAAAGACCATAAGAAAATTAAACCATAA6900AGCTATATTAATAAATTGTAACCCAGAAACTGTAAGTACAGATTATGATGAAAGTGATCG6960TCTATATTTTGATGAAATAACAACAGAAGTTATAAAATTTATATATAACTTTGAAAATAG7020TAATGGTGTGATTATAGCTTTTGGTGGACAAACATCAAATAATTTAGTATTTAGTTTATA7080TAAAAATAATGTAAATATATTAGGATCAGTGCACAAAGTGTTGATTGTTGTGAAAATAGG7140AATAAATTTTCGCACTTATGTGATTCTTAAAATTGATCAACCGAAATGGAATAAATTTAC7200AAAATTATCCAAGGCTATACAATTTGCTAATGAGGTAAAATTTCCTGTATTAGTAAGACC7260ATCGTATGTATTATCTGGTGCAGCTATGAGAGTTGTAAATTGTTTTGAAGAATTAAAAAA7320CTTTTTAATGAAGGCAGCTATTGTTAGTAAAGATAATCCTGTTGTAATATCAAAATTTAT7380TGAGAATGCTAAAGAAATAGAAATAGATTGTGTTAGTAAAAATGGTAAAATAATTAATTA7440TGCTATATCTGAACATGTTGAAAATGCTGGTGTACATTCAGGTGATGCAACATTAATATT7500ACCTGCACAAAATATATATGTTGAAACACATAGGAAAATAAAGAAAATATCCGAAAAGAT7560TTCAAAATCATTAAATATATCTGGTCCATTTAATATACAATTTATATGTCATCAAAATGA7620AATAAAAATTATTGAATGTAATTTAAGAGCATCTAGAACTTTTCCATTTATATCAAAAGC7680TCTAAATCTAAACTTTATAGATTTAGCTACAAGGATATTAATGGGTTATGACGTCAAACC7740AATTAATATATCATTAATTGATTTAGAATATACAGCTGTAAAAGCACCGATTTTCTCATT7800TAATAGATTACATGGATCAGATTGTATACTAGGTGTAGAAATGAAATCTACAGGTGAAGT7860AGCATGTTTTGGTTTAAATAAATATGAAGCTTTATTAAAATCATTAATAGCTACAGGTAT7920GAAGTTACCCAAAAAATCAATACTTATAAGTATTAAAAATTTAAATAATAAATTAGCTTT7980TGAAGAACCGTTCCAATTATTATTTTTAATGGGATTTACAATATATGCGACTGAAGGTAC8040GTATGATTTCTACTCTAAATTTTTAGAATCTTTTAATGTTAATAAAGGTTCTAAATTTCA8100TCAAAGACTTATTAAAGTTCATAATAAAAATGCAGAAAATATATCACCAAATACAACAGA8160TTTAATTATGAATCATAAAGTTGAAATGGTTATTAATATAACTGATACATTAAAAACAAA8220GGTTAGTTCAAATGGTTATAAAATTAGAAGATTAGCATCAGATTTCCAGGTTCCTTTAAT8280AACTAATATGAAACTTTGTTCTCTTTTTATTGACTCATTATATAGAAAATTCTCAAGACA8340AAAGGAAAGAAAATCATTCTATACCATAAAGAGTTATGACGAATATATAAGTTTGGTATA8400AGCAAGAAATTATTCAATAAATTCGATTTAACATTACTTATTTATGTATTTATTAACTTT8460CATTCCATAACAACATGAAAAGTATAAATATATAAATAGTAATATATAATATATAATATA8520TATATATATATATATATATATATTTATTTATTTAATTATATTTACGTTTAAATATTAATA8580AATGTTTTTATTAAATATGATCATTAATTTATATTGATTTATTTTTTTATAAATTTTTGT8640TATATATACAAATTTTATTTATTCACTCATATGTATAAACCAAAATGGTTTTTTCAATTT8700ACAAATAATTTTATAATTTTAATAAATTTATTAATTATAAAAAAAATAAAAATATATAAA8760CATTAAAATGTATAAATTCTTTTAATTATATAATAATTTATAAATGTTATGATTTTTTTA8820AAAAATTCAACGAAAAAAAAGAGGAACTGTATATACAAAAGGGACTATATATATGTATAT8880ATATATATATATATATATGTTTTTTTTTCCTTATTCTAGA8920(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 2391 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetTyrIleSerPheLysTyrAsnLeuTyrIleTyrIleTyrIleTyr151015IleTyrIlePheValLeuIleAspPheLysThrValGlyArgLeuIle202530LeuGluAspGlyAsnGluPheValGlyTyrSerValGlyTyrGluGly354045CysLysGlyAsnAsnSerIleSerCysHisLysGluTyrArgAsnIle505560IleAsnAsnAspAsnSerLysAsnSerAsnAsnSerPheCysAsnAsn65707580GluGluAsnAsnLeuLysAspAspLeuLeuTyrLysAsnSerArgLeu859095GluAsnGluAspPheIleValThrGlyGluValIlePheAsnThrAla100105110MetValGlyTyrProGluAlaLeuThrAspProSerTyrPheGlyGln115120125IleLeuValLeuThrPheProSerIleGlyAsnTyrGlyIleGluLys130135140ValLysHisAspGluThrPheGlyLeuValGlnAsnPheGluSerAsn145150155160LysIleGlnValGlnGlyLeuValIleCysGluTyrSerLysGlnSer165170175TyrHisTyrAsnSerTyrIleThrLeuSerGluTrpLeuLysIleTyr180185190LysIleProCysIleGlyGlyIleAspThrArgAlaLeuThrLysLeu195200205LeuArgGluLysGlySerMetLeuGlyLysIleValIleTyrLysAsn210215220ArgGlnHisIleAsnLysLeuTyrLysGluIleAsnLeuPheAspPro225230235240GlyAsnIleAspThrLeuLysTyrValCysAsnHisPheIleArgVal245250255IleLysLeuAsnAsnIleThrTyrAsnTyrLysAsnLysGluGluPhe260265270AsnTyrThrAsnGluMetIleThrAsnAspSerSerMetGluAspHis275280285AspAsnGluIleAsnGlySerIleSerAsnPheAsnAsnCysProSer290295300IleSerSerPheAspLysSerGluSerLysAsnValIleAsnHisThr305310315320LeuLeuArgAspLysMetAsnLeuIleThrSerSerGluGluTyrLeu325330335LysAspLeuHisAsnCysAsnPheSerAsnSerSerAspLysAsnAsp340345350SerPhePheLysLeuTyrGlyIleCysGluTyrAspLysTyrLeuIle355360365AspLeuGluGluAsnAlaSerPheHisTyrAsnAsnValAspGluTyr370375380GlyTyrTyrAspValAsnLysAsnThrAsnIleLeuSerAsnAsnLys385390395400IleGluGlnAsnAsnAsnAsnGluAsnAsnLysAsnAsnLysAsnAsn405410415AsnAsnAsnGluValAspTyrIleLysLysAspGluAspAsnAsnVal420425430AsnSerLysValPheTyrSerGlnTyrAsnAsnAsnAlaGlnAsnAsn435440445GluHisThrGluPheAsnLeuAsnAsnAspTyrSerThrTyrIleArg450455460LysLysMetLysAsnGluGluPheLeuAsnLeuValAsnLysArgLys465470475480ValAspHisLysGluLysIleIleValIleValAspCysGlyIleLys485490495AsnSerIleIleLysAsnLeuIleArgHisGlyMetAspLeuProLeu500505510ThrTyrIleIleValProTyrTyrTyrAsnPheAsnHisIleAspTyr515520525AspAlaValLeuLeuSerAsnGlyProGlyAspProLysLysCysAsp530535540PheLeuIleLysAsnLeuLysAspSerLeuThrLysAsnLysIleIle545550555560PheGlyIleCysLeuGlyAsnGlnLeuLeuGlyIleSerLeuGlyCys565570575AspThrTyrLysMetLysTyrGlyAsnArgGlyValAsnGlnProVal580585590IleGlnLeuValAspAsnIleCysTyrIleThrSerGlnAsnHisGly595600605TyrCysLeuLysLysLysSerIleLeuLysArgLysGluLeuAlaIle610615620SerTyrIleAsnAlaAsnAspLysSerIleGluGlyIleSerHisLys625630635640AsnGlyArgPheTyrSerValGlnPheHisProGluGlyAsnAsnGly645650655ProGluAspThrSerPheLeuPheLysAsnPheLeuLeuAspIlePhe660665670AsnLysLysLysGlnTyrArgGluTyrLeuGlyTyrAsnIleIleTyr675680685IleLysLysLysValLeuLeuLeuGlySerGlyGlyLeuCysIleGly690695700GlnAlaGlyGluPheAspTyrSerGlyThrGlnAlaIleLysSerLeu705710715720LysGluCysGlyIleTyrValIleLeuValAsnProAsnIleAlaThr725730735ValGlnThrSerLysGlyLeuAlaAspLysValTyrPheLeuProVal740745750AsnCysGluPheValGluLysIleIleLysLysGluLysProAspPhe755760765IleLeuCysThrPheGlyGlyGlnThrAlaLeuAsnCysAlaLeuMet770775780LeuAspGlnLysLysValLeuLysLysAsnAsnCysGlnCysLeuGly785790795800ThrSerLeuGluSerIleArgIleThrGluAsnArgThrLeuPheAla805810815GluLysLeuLysGluIleAsnGluArgIleAlaProTyrGlySerAla820825830LysAsnValAsnGlnAlaIleAspIleAlaAsnLysIleGlyTyrPro835840845IleLeuValArgThrThrPheSerLeuGlyGlyLeuAsnSerSerPhe850855860IleAsnAsnGluGluGluLeuIleGluLysCysAsnLysIlePheLeu865870875880GlnThrAspAsnGluIlePheIleAspLysSerLeuGlnGlyTrpLys885890895GluIleGluTyrGluLeuLeuArgAspAsnLysAsnAsnCysIleAla900905910IleCysAsnMetGluAsnIleAspProLeuGlyIleHisThrGlyAsp915920925SerIleValValAlaProSerGlnThrLeuSerAsnTyrGluTyrTyr930935940LysPheArgGluIleAlaLeuLysValIleThrHisLeuAsnIleIle945950955960GlyGluCysAsnIleGlnPheGlyIleAsnProGlnThrGlyGluTyr965970975CysIleIleGluValAsnAlaArgLeuSerArgSerSerAlaLeuAla980985990SerLysAlaThrGlyTyrProLeuAlaTyrIleSerAlaLysIleAla99510001005LeuGlyTyrAspLeuIleSerLeuLysAsnSerIleThrLysLysThr101010151020ThrAlaCysPheGluProSerLeuAspTyrIleThrThrLysIlePro1025103010351040ArgTrpAspLeuAsnLysPheGluPheAlaSerAsnThrMetAsnSer104510501055SerMetLysSerValGlyGluValMetSerIleGlyArgThrPheGlu106010651070GluSerIleGlnLysSerLeuArgCysIleAspAspAsnTyrLeuGly107510801085PheSerAsnThrTyrCysIleAspTrpAspGluLysLysIleIleGlu109010951100GluLeuLysAsnProSerProLysArgIleAspAlaIleHisGlnAla1105111011151120PheHisLeuAsnMetProMetAspLysIleHisGluLeuThrHisIle112511301135AspTyrTrpPheLeuHisLysPheTyrAsnIleTyrAsnLeuGlnAsn114011451150LysLeuLysThrLeuLysLeuGluGlnLeuSerPheAsnAspLeuLys115511601165TyrPheLysLysHisGlyPheSerAspLysGlnIleAlaHisTyrLeu117011751180SerPheAsnThrSerAspAsnAsnAsnAsnAsnAsnAsnIleSerSer1185119011951200CysArgValThrGluAsnAspValMetLysTyrArgGluLysLeuGly120512101215LeuPheProHisIleLysValIleAspThrLeuSerAlaGluPhePro122012251230AlaLeuThrAsnTyrLeuTyrLeuThrTyrGlnGlyGlnGluHisAsp123512401245ValLeuProLeuAsnMetLysArgLysLysIleCysThrLeuAsnAsn125012551260LysArgAsnAlaAsnLysLysLysValHisValLysAsnHisLeuTyr1265127012751280AsnGluValValAspAspLysAspThrGlnLeuHisLysGluAsnAsn128512901295AsnAsnAsnAsnMetAsnSerGlyAsnValGluAsnLysCysLysLeu130013051310AsnLysGluSerTyrGlyTyrAsnAsnSerSerAsnCysIleAsnThr131513201325AsnAsnIleAsnIleGluAsnAsnIleCysHisAspIleSerIleAsn133013351340LysAsnIleLysValThrIleAsnAsnSerAsnAsnSerIleSerAsn1345135013551360AsnGluAsnValGluThrAsnLeuAsnCysValSerGluArgAlaGly136513701375SerHisHisIleTyrGlyLysGluGluLysSerIleGlySerAspAsp138013851390ThrAsnIleLeuSerAlaGlnAsnSerAsnAsnAsnPheSerCysAsn139514001405AsnGluAsnMetAsnLysAlaAsnValAspValAsnValLeuGluAsn141014151420AspThrLysLysArgGluAspIleAsnThrThrThrValPheMetGlu1425143014351440GlyGlnAsnSerValIleAsnAsnLysAsnLysGluAsnSerSerLeu144514501455LeuLysGlyAspGluGluAspIleValMetValAsnLeuLysLysGlu146014651470AsnAsnTyrAsnSerValIleAsnAsnValAspCysArgLysLysAsp147514801485MetAspGlyLysAsnIleAsnAspGluCysLysThrTyrLysLysAsn149014951500LysTyrLysAspMetGlyLeuAsnAsnAsnIleValAspGluLeuSer1505151015151520AsnGlyThrSerHisSerThrAsnAspHisLeuTyrLeuAspAsnPhe152515301535AsnThrSerAspGluGluIleGlyAsnAsnLysAsnMetAspMetTyr154015451550LeuSerLysGluLysSerIleSerAsnLysAsnProGlyAsnSerTyr155515601565TyrValValAspSerValTyrAsnAsnGluTyrLysIleAsnLysMet157015751580LysGluLeuIleAspAsnGluAsnLeuAsnAspGluTyrAsnAsnAsn1585159015951600ValAsnMetAsnCysSerAsnTyrAsnAsnAlaSerAlaPheValAsn160516101615GlyLysAspArgAsnAspAsnLeuGluAsnAspCysIleGluLysAsn162016251630MetAspHisThrTyrLysHisTyrAsnArgLeuAsnAsnArgArgSer163516401645ThrAsnGluArgMetMetLeuMetValAsnAsnGluLysGluSerAsn165016551660HisGluLysGlyHisArgArgAsnGlyLeuAsnLysLysAsnLysGlu1665167016751680LysAsnMetGluLysAsnLysGlyLysAsnLysAspLysLysAsnTyr168516901695HisTyrValAsnHisLysArgAsnAsnGluTyrAsnSerAsnAsnIle170017051710GluSerLysPheAsnAsnTyrValAspAspIleAsnLysLysGluTyr171517201725TyrGluAspGluAsnAspIleTyrTyrPheThrHisSerSerGlnGly173017351740AsnAsnAspAspLeuSerAsnAspAsnTyrLeuSerSerGluGluLeu1745175017551760AsnThrAspGluTyrAspAspAspTyrTyrTyrAspGluAspGluGlu176517701775AspAspTyrAspAspAspAsnAspAspAspAspAspAspAspAspAsp178017851790GlyGluAspGluGluAspAsnAspTyrTyrAsnAspAspGlyTyrAsp179518001805SerTyrAsnSerLeuSerSerSerArgIleSerAspValSerSerVal181018151820IleTyrSerGlyAsnGluAsnIlePheAsnGluLysTyrAsnAspIle1825183018351840GlyPheLysIleIleAspAsnArgAsnGluLysGluLysGluLysLys184518501855LysCysPheIleValLeuGlyCysGlyCysTyrArgIleGlySerSer186018651870ValGluPheAspTrpSerAlaIleHisCysValLysThrIleArgLys187518801885LeuAsnHisLysAlaIleLeuIleAsnCysAsnProGluThrValSer189018951900ThrAspTyrAspGluSerAspArgLeuTyrPheAspGluIleThrThr1905191019151920GluValIleLysPheIleTyrAsnPheGluAsnSerAsnGlyValIle192519301935IleAlaPheGlyGlyGlnThrSerAsnAsnLeuValPheSerLeuTyr194019451950LysAsnAsnValAsnIleLeuGlySerValHisLysValLeuIleVal195519601965ValLysIleGlyIleAsnPheArgThrTyrValIleLeuLysIleAsp197019751980GlnProLysTrpAsnLysPheThrLysLeuSerLysAlaIleGlnPhe1985199019952000AlaAsnGluValLysPheProValLeuValArgProSerTyrValLeu200520102015SerGlyAlaAlaMetArgValValAsnCysPheGluGluLeuLysAsn202020252030PheLeuMetLysAlaAlaIleValSerLysAspAsnProValValIle203520402045SerLysPheIleGluAsnAlaLysGluIleGluIleAspCysValSer205020552060LysAsnGlyLysIleIleAsnTyrAlaIleSerGluHisValGluAsn2065207020752080AlaGlyValHisSerGlyAspAlaThrLeuIleLeuProAlaGlnAsn208520902095IleTyrValGluThrHisArgLysIleLysLysIleSerGluLysIle210021052110SerLysSerLeuAsnIleSerGlyProPheAsnIleGlnPheIleCys211521202125HisGlnAsnGluIleLysIleIleGluCysAsnLeuArgAlaSerArg213021352140ThrPheProPheIleSerLysAlaLeuAsnLeuAsnPheIleAspLeu2145215021552160AlaThrArgIleLeuMetGlyTyrAspValLysProIleAsnIleSer216521702175LeuIleAspLeuGluTyrThrAlaValLysAlaProIlePheSerPhe218021852190AsnArgLeuHisGlySerAspCysIleLeuGlyValGluMetLysSer219522002205ThrGlyGluValAlaCysPheGlyLeuAsnLysTyrGluAlaLeuLeu221022152220LysSerLeuIleAlaThrGlyMetLysLeuProLysLysSerIleLeu2225223022352240IleSerIleLysAsnLeuAsnAsnLysLeuAlaPheGluGluProPhe224522502255GlnLeuLeuPheLeuMetGlyPheThrIleTyrAlaThrGluGlyThr226022652270TyrAspPheTyrSerLysPheLeuGluSerPheAsnValAsnLysGly227522802285SerLysPheHisGlnArgLeuIleLysValHisAsnLysAsnAlaGlu229022952300AsnIleSerProAsnThrThrAspLeuIleMetAsnHisLysValGlu2305231023152320MetValIleAsnIleThrAspThrLeuLysThrLysValSerSerAsn232523302335GlyTyrLysIleArgArgLeuAlaSerAspPheGlnValProLeuIle234023452350ThrAsnMetLysLeuCysSerLeuPheIleAspSerLeuTyrArgLys235523602365PheSerArgGlnLysGluArgLysSerPheTyrThrIleLysSerTyr237023752380AspGluTyrIleSerLeuVal23852390__________________________________________________________________________

Claims

1. An isolated nucleic acid molecule encoding Plasmodium falciparum carbamoyl phosphate synthetase II, or a portion thereof, wherein the sequence of the nucleic acid molecule comprises a sequence selected from the group consisting of nucleotides 1226 to 8401, nucleotides 1226 to 1975, nucleotides 1976 to 2671, nucleotides 2672 to 3295, nucleotides 3296 to 4987, nucleotides 4988 to 6796, nucleotides 6797 to 8398, nucleotides 1226 to 4585, nucleotides 3296 to 7891, and nucleotides 3296 to 8398 of SEQ. ID. NO: 1.

2. The nucleic acid molecule of claim 1 wherein the sequence of the nucleic acid molecule comprises SEQ. ID. NO: 1.

3. A vector comprising the nucleic acid of claim 1.

4. A vector comprising the nucleic acid of claim 3.